Sigilon Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$23.5M
Industry:Biotech
Founded:2015
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Sigilon's estimated annual revenue is currently $17.1M per year.
  • Sigilon's estimated revenue per employee is $155,000
  • Sigilon's total funding is $23.5M.

Employee Data

  • Sigilon has 110 Employees.
  • Sigilon grew their employee count by 4% last year.
  • Sigilon currently has 2 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Harnessing the full power of cell therapeutics. Cambridge, MA

keywords:N/A

110

Number of Employees

$17.1M

Revenue (est)

2

Current Jobs

4%

Employee Growth %

$23.5M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
James WatsonChief Business Officer And President Islet Cell Therapy
Anne AltmeyerChief Business OfficerEmail Available
Derrick AllenAssociate Principal Scientist
Vanya SagarVP, Head of Human ResourcesEmail Available
Susan DrapeauVP, Head Device and Delivery Engineering
Anthony GarritySenior Manager, ITEmail Available
Michael BaldwinDirector Of Business Development
Marina MihovaDirector Clinical Operations
Jelena GarafaloSenior Director Medical AffairsEmail Available
Marianthi PapakostaDirector, Pipeline Development

Sigilon News

27/08/2019 - Sigilon Therapeutics Receives Orphan Drug Designation for ...

“This is the first of what we hope will be multiple Orphan Drug Designations for Sigilon as we continue progressing novel therapies for chronic ...

04/09/2019 - Investigational Therapy for Hemophilia A Granted Orphan ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to SIG-001 (Sigilon Therapeutics) for the treatment of ...

28/08/2019 - FDA Grants Sigilon Therapeutic's SIG-001 Orphan Drug ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Sigilon Therapeutics' candidate cell therapy, called SIG-001, ...

Sigilon Executive Hires

DateNameTitleReference
2018-01-05David MollerChief Scientific OfficerArticle
2018-08-15Rogerio VivaldiCEOArticle
2018-11-14Deya CorzoChief Medical OfficerArticle